A5052378579- Mast cells and histamine
- Urticaria and Related Conditions
- Food Allergy and Anaphylaxis Research
- Asthma and respiratory diseases
- Dermatology and Skin Diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Allergic Rhinitis and Sensitization
- Autoimmune Bullous Skin Diseases
- Drug-Induced Adverse Reactions
- Eosinophilic Disorders and Syndromes
- melanin and skin pigmentation
- Contact Dermatitis and Allergies
- Hair Growth and Disorders
- Immune Cell Function and Interaction
- Eosinophilic Esophagitis
- Olfactory and Sensory Function Studies
- Medical and Health Sciences Research
- Polyamine Metabolism and Applications
- Research on Leishmaniasis Studies
- Tuberculosis Research and Epidemiology
- Immunodeficiency and Autoimmune Disorders
- Skin Protection and Aging
- Advancements in Transdermal Drug Delivery
- Body Image and Dysmorphia Studies
- scientometrics and bibliometrics research
Charité - Universitätsmedizin Berlin
2016-2025
Freie Universität Berlin
2019-2025
Fraunhofer Institute for Translational Medicine and Pharmacology
2021-2025
Humboldt-Universität zu Berlin
2004-2025
Stanford University
2024
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
2020-2023
Orthopädische Universitätsklinik
2023
Misgav Ladach
2022
Universidad de Salamanca
2022
Medical University of Vienna
2021
This update and revision of the international guideline for urticaria was developed following methods recommended by Cochrane Grading Recommendations Assessment, Development Evaluation (GRADE) working group. It is a joint initiative Dermatology Section European Academy Allergology Clinical Immunology (EAACI), Global Allergy Asthma Network (GA²LEN) its Urticaria Angioedema Centers Reference Excellence (UCAREs ACAREs), Forum (EDF; EuroGuiDerm), Asia Pacific Association Allergy, with...
Abstract Mastocytosis is an emerging differential diagnosis in patients with more or less specific mediator‐related symptoms. In some of these patients, typical skin lesions are found and the mastocytosis can be established. other cases, however, absent, which represents a diagnostic challenge. light this unmet need, we developed algorithm for suspected mastocytosis. adult skin, bone marrow ( BM ) biopsy should considered, regardless basal serum tryptase concentration. adults without who...
In physical urticaria, exogenous factors such as thermal triggers, solar radiation and mechanic triggers including friction or pressure are responsible for the elicitation of symptoms in skin patients. Avoidance respective stimulus is usually difficult impossible, many patients not sufficiently treated with standard antihistamines. We report that treatment omalizumab (Xolair®) 7 urticarias [solar urticaria (n = 2), factitia/symptomatic dermographism cold delayed localized heat urticaria]...
Quality of life, which is impaired in patients with chronic spontaneous urticaria (CSU), influenced by comorbid mental disorders. The aim this study was to assess the prevalence and spectrum disorders determine levels emotional distress CSU. One hundred CSU were investigated for (by specialized diagnostic interviews psychometric instruments), Global Severity Index Symptom Check List; SCL-90R GSI) underlying causes their dermatological assessment). Forty-eight percent diagnosed one or more...
Abstract Background S chnitzler syndrome (SchS) is a rare disease with suspected autoinflammatory background that shares several clinical symptoms, including urticarial rash, fever episodes, arthralgia, and bone muscle pain cryopyrin‐associated periodic syndromes ( CAPS ). Cryopyrin‐associated respond to treatment interleukin‐1 antagonists, single case reports of have shown improvement following the blocker anakinra. This study evaluated effects antagonist rilonacept on signs symptoms SchS....
Abstract Background Patients with systemic mastocytosis (SM) may suffer from mast cell (MC) mediator‐related symptoms insufficiently controlled by conventional therapy. Omalizumab is an established treatment in other MC‐driven diseases, but experiences SM are limited. Objective To assess the efficacy and safety of omalizumab SM. Methods In our patient cohort, we evaluated all patients treated omalizumab. A physician global assessment type severity was performed at baseline, 3 6 months latest...
BackgroundChronic urticaria (CU) is a debilitating mast cell–driven disease, often refractory to standard therapy (ie, antihistamines). Lirentelimab, an anti–sialic acid–binding immunoglobulin-like lectin 8 mAb, selectively inhibits cells and depletes eosinophils.ObjectiveWe sought determine safety efficacy of lirentelimab in patients with CU.MethodsThis phase 2a study enrolled CU up 4-fold H1-antihistamine doses. Patients received 6 monthly intravenous doses (0.3, 1, 3 mg/kg). Primary end...
Mast cell activation (MCA) is common and occurs in a number of pathologic conditions, including IgE-dependent independent allergic reactions, atopic disorders, autoimmune processes, mastocytosis. In subset patients, no underlying disease known trigger MCA are found. When the symptoms severe, systemic, recurrent, accompanied by diagnostic increase serum tryptase level or other mast mediators, an syndrome (MCAS) may be diagnosed. these typically respond to drugs suppressing MCA, mediator...
BackgroundIndolent systemic mastocytosis (ISM) is a clonal mast-cell disease driven by the KIT D816V mutation. We assessed efficacy and safety of avapritinib versus placebo, both with best supportive care, in patients ISM.MethodsWe randomized moderate to severe ISM (total symptom score [TSS] ≥28; scores range from 0 110, higher numbers indicating more symptoms) two one 25 mg once daily (n=141) or placebo (n=71). The primary end point was mean change TSS based on 14-day average...
<i>Background:</i> Patients with chronic urticaria (CU) frequently exhibit positive skin test reactions to autologous serum (ASST). Therapies aimed at inducing tolerance circulating histamine-releasing factors in ASST+ CU patients, e.g. by treatment whole blood (AWB), have not yet been tested. <i>Objective:</i> To whether patients can benefit from repeated low-dose intramuscular injections of AWB. <i>Methods:</i> We characterized severity and duration,...